Werewolf Therapeutics Net Income
| HOWL Stock | USD 0.67 0.01 1.77% |
As of the 2nd of February, Werewolf Therapeutics maintains the Mean Deviation of 4.7, standard deviation of 7.21, and Market Risk Adjusted Performance of (0.61). Werewolf Therapeutics technical analysis makes it possible for you to employ past prices and volume data with the intention to determine a pattern that calculates the direction of the company's future prices. Please check out Werewolf Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Werewolf Therapeutics is priced fairly, providing market reflects its latest price of 0.6717 per share. As Werewolf Therapeutics is a penny stock we also advise to confirm its jensen alpha numbers.
Werewolf Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.6742 | Earnings Share (1.62) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -63.5 M | -60.3 M | |
| Net Loss | -61.9 M | -58.8 M | |
| Net Loss | -63.5 M | -60.3 M | |
| Net Loss | (1.87) | (1.96) | |
| Net Income Per E B T | 1.14 | 1.13 |
Werewolf | Net Income | Build AI portfolio with Werewolf Stock |
Historical Net Income data for Werewolf Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Werewolf Therapeutics represents a compelling investment opportunity.
Latest Werewolf Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Werewolf Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Werewolf Therapeutics financial statement analysis. It represents the amount of money remaining after all of Werewolf Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Werewolf Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Werewolf Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (70.52 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Werewolf Net Income Regression Statistics
| Arithmetic Mean | (26,929,813) | |
| Coefficient Of Variation | (84.42) | |
| Mean Deviation | 20,163,405 | |
| Median | (10,990,000) | |
| Standard Deviation | 22,733,778 | |
| Sample Variance | 516.8T | |
| Range | 59.5M | |
| R-Value | (0.84) | |
| Mean Square Error | 165.1T | |
| R-Squared | 0.70 | |
| Significance | 0.000028 | |
| Slope | (3,767,848) | |
| Total Sum of Squares | 8269.2T |
Werewolf Net Income History
Other Fundumenentals of Werewolf Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Werewolf Therapeutics Net Income component correlations
Werewolf Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Werewolf Therapeutics is extremely important. It helps to project a fair market value of Werewolf Stock properly, considering its historical fundamentals such as Net Income. Since Werewolf Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Werewolf Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Werewolf Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Werewolf Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Werewolf Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Werewolf Therapeutics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Werewolf Therapeutics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Werewolf Therapeutics or generate 0.0% return on investment in Werewolf Therapeutics over 90 days. Werewolf Therapeutics is related to or competes with IO Biotech, Spruce Biosciences, OUTLOOK THERAPEUTICS, Adicet Bio, NRX Pharmaceuticals, Lite Strategy, and OS Therapies. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the bodys immune... More
Werewolf Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Werewolf Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Werewolf Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 51.9 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.69 |
Werewolf Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Werewolf Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Werewolf Therapeutics' standard deviation. In reality, there are many statistical measures that can use Werewolf Therapeutics historical prices to predict the future Werewolf Therapeutics' volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.19) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.62) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Werewolf Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Werewolf Therapeutics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.61) | |||
| Mean Deviation | 4.7 | |||
| Coefficient Of Variation | (644.54) | |||
| Standard Deviation | 7.21 | |||
| Variance | 51.97 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.19) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.62) | |||
| Maximum Drawdown | 51.9 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.69 | |||
| Skewness | (2.03) | |||
| Kurtosis | 11.5 |
Werewolf Therapeutics Backtested Returns
Werewolf Therapeutics shows Sharpe Ratio of -0.0888, which attests that the company had a -0.0888 % return per unit of risk over the last 3 months. Werewolf Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Werewolf Therapeutics' Mean Deviation of 4.7, market risk adjusted performance of (0.61), and Standard Deviation of 7.21 to validate the risk estimate we provide. The firm maintains a market beta of 1.82, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Werewolf Therapeutics will likely underperform. At this point, Werewolf Therapeutics has a negative expected return of -0.64%. Please make sure to check out Werewolf Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Werewolf Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.48 |
Average predictability
Werewolf Therapeutics has average predictability. Overlapping area represents the amount of predictability between Werewolf Therapeutics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Werewolf Therapeutics price movement. The serial correlation of 0.48 indicates that about 48.0% of current Werewolf Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.48 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Werewolf Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Werewolf Therapeutics reported net income of (70.52 Million). This is 120.66% lower than that of the Biotechnology sector and 200.67% lower than that of the Health Care industry. The net income for all United States stocks is 112.35% higher than that of the company.
Werewolf Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Werewolf Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics of similar companies.Werewolf Therapeutics is currently under evaluation in net income category among its peers.
Werewolf Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Werewolf Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Werewolf Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Werewolf Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 328 K | Renaissance Technologies Corp | 2025-06-30 | 316.3 K | Alyeska Investment Group, L.p. | 2025-06-30 | 235.7 K | Goldman Sachs Group Inc | 2025-06-30 | 227.4 K | State Street Corp | 2025-06-30 | 119.2 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 103.8 K | Bridgeway Capital Management, Llc | 2025-06-30 | 102 K | Aqr Capital Management Llc | 2025-06-30 | 92.2 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 84.4 K | Ra Capital Management, Llc | 2025-06-30 | 6.7 M | Mpm Asset Management, Llc | 2025-06-30 | 4.3 M |
Werewolf Fundamentals
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 6.76 M | ||||
| Shares Outstanding | 48.54 M | ||||
| Shares Owned By Insiders | 5.61 % | ||||
| Shares Owned By Institutions | 41.99 % | ||||
| Number Of Shares Shorted | 2.29 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 52.22 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (50.48 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Short Ratio | 2.54 X | ||||
| Earnings Per Share | (1.62) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 5.2 | ||||
| Number Of Employees | 39 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 32.11 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
| Net Asset | 126.93 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.